

Bilateral internal mammary artery grafting in CABG surgery: an extra 20 minutes for an extra 20 years...

Teresa M. Kieser*, MD, FRCS(C), FACS

Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada

Bilateral internal mammary artery (BIMA) grafting has been the operation of the future for 25 years - it must now arrive! One cannot talk about BIMA grafting without first discussing why venous bypass grafts are no longer best practice.

Why are vein grafts so bad?

Because veins were never meant to be arteries. It is true that some vein grafts last 30 years but the majority don't. The blood pressure in veins is 25-30 mmHg; the pressure in arteries is 120/80 mmHg. So when a vein is expected to do the job of an artery, it all too often fails. In 1996, FitzGibbon¹ studied 5,065 bypass grafts from 1969 to 1994: early graft patency (<3 weeks) was 88%. In 2010, the results for early patency were still exactly the same: 88.2% patency in 322 venous grafts at ≤7 days in a study by Kim² versus 98.9% (3,495/3,535) in arterial grafts. In a 2008 study meant to determine if edifoligide would prevent vein graft failure due to neointimal hyperplasia, the one-year venous graft patency was 74.3%³. In FitzGibbon's study, "A" vein graft patency at one year was 76%. Despite improvements in every area of medicine and surgery over decades, vein graft patency has remained the same: unacceptable. As time goes on, vein graft patency worsens: at 10 years, 48% are "A" grafts and at ≥15 years 40% are patent¹.

Why are BIMA grafts so good?

Because God made them that way. The literature is replete with the benefits of BIMA grafting: decreased risk of death, reoperation and angioplasty⁴, improved in-hospital mortality⁵, increased long-term survival⁶⁻⁹. BIMA is also better in certain subgroups of patients, e.g., those with reduced ejection fraction¹⁰ and patients with diabetes^{11,12}. Use of BIMA has been shown to have better five-year reintervention-free survival compared with drug-eluting stents in diabetic patients¹³. Most recently, Kurlansky¹⁴ demonstrated that use of BIMA reverses the influence of gender on CABG outcomes short and long-term, ameliorating both the increased perioperative mortality in female patients and the reduced long-term survival of male patients. The cut-off age for benefit of BIMA grafting ranges from 65 to 74 years of age^{8,15-17}. The low incidence of BIMA grafting is no longer justifiable with the evidence to date.

Why do surgeons use veins?

Because this is how they were taught, immediate results are good, it's easier, inertia (it is hard to leave one's "comfort zone" and perform more technically demanding procedures with the requisite learning curve). BIMA grafting devascularises the sternum more than single mammary harvest and predisposes to deep sternal

*Corresponding author: Foothills Medical Centre, Room C 814, 1403 29th St NW, Calgary, Alberta, T2N 2T9, Canada.
E-mail: t.kieserprieur@ucalgary.ca

wound infection. In the United States, the centres for Medicare and Medicaid Services no longer reimburse for the extra care necessary for treatment of deep sternal wound infection as this is deemed a “never event”¹⁸. World-famous chefs do not use “freezer-burned chicken” and “one-week-old lettuce” to create a culinary masterpiece; they use the very best ingredients. Then why do we as surgeons use a vein? Fast-food mentality?

Why do surgeons not use BIMA?

Because BIMA harvest is more time-consuming, surgeons like to be “slick”. In some respects, we surgeons have not evolved much from the early days of barber-shop surgery. We now have general anaesthesia, so we do not have to be so “quick”. It may take an extra 20 minutes in a three- to four-hour operation to use the second mammary (principally the harvest time). What a payback for patients – an extra 20 minutes for an extra 20 years....

In a survey of 101 of 147 Canadian surgeons by Mastrobuoni et al¹⁹, the main factors influencing BIMA use by surgeons were: risk of sternal wound infection for 35% of surgeons, the reluctance to believe in the superiority of the right internal mammary artery (RIMA) over the saphenous vein for long-term outcome for 30% of surgeons, limited length of the RIMA for 28% of surgeons, and increased operative time or bleeding for 6% of surgeons.

One famous surgeon (I am not sure who) said “I think that maybe what we should be doing is just put two internal mammaries on the heart somewhere and leave it at that”. This is a worthy thought: two IMAs on the two biggest territories (LAD, CIRC, or RCA) would leave the patient with single-vessel disease which (if symptomatic) could (if amenable) be addressed with PCI; this would perhaps be a more meaningful “hybrid” procedure than just the LIMA-LAD and the other two territories with DES stents.

The team effort

There is a common theme emerging from cardiologists all over the world – they “yearn for BIMA grafting”. Why is this? Venous graft disease is almost impossible to deal with for two reasons: 1) patients with serious venous graft disease often have a patent LIMA to LAD on which most surgeons will be reluctant to perform reoperation for fear of damage to the IMA upon chest re-entry; 2) PCI is fraught with the danger of embolisation causing serious myocardial damage, and the atherosclerosis that develops in vein grafts is the biggest challenge for any type of stent. Drug-eluting stents are somewhat better²⁰, but nothing fully corrects the problem of vein graft atherosclerosis, except not using veins to begin with. Please do not misunderstand – there is a place for using the vein. It has saved many a patient’s life, but its use should be the exception rather than the rule.

Cardiologists refer business to surgeons: as cardiac surgeons we are heartened when we see beautiful BIMA grafts studied years after CABG surgery. We rise to the occasion when the following is proposed: “If you would do a left internal mammary artery (LIMA) to the LAD and a RIMA to the RCA (or CIRC), we can do PCI for the third if the patient suffers angina”. And then there is tough love – what if cardiologists didn’t send surgeons CABG cases unless

surgeons do BIMA(!)? Detailed discussion of cases between surgeons and cardiologists are often enlightening for both. We should learn to talk to each other - patients can only benefit...

Conflict of interest statement

T. Kieser is a consultant for Medistim ASA, Medistim USA and Ethicon Endosurgery.

References

1. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. *J Am Coll Cardiol.* 1996;28:616-26.
2. Kim KB, Kim JS, Kang HJ, Koo BK, Kim HS, Oh BH, Park YB. Ten-year experience with off-pump coronary artery bypass grafting: lessons learned from early postoperative angiography. *J Thorac Cardiovasc Surg.* 2010;139:256-62.
3. Magee MJ, Alexander JH, Hafley G, Ferguson TB Jr, Gibson CM, Harrington RA, Peterson ED, Califf RM, Kouchoukos NT, Herbert MA, Mack MJ; PREVENT IV Investigators. Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. *Ann Thorac Surg.* 2008;85:494-9; discussion 499-500.
4. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, McCarthy PM, Cosgrove DM. Two internal thoracic artery grafts are better than one. *J Thorac Cardiovasc Surg.* 1999;117:855-72.
5. Itagaki S, Cavallaro P, Adams DH, Chikwe J. Bilateral internal mammary artery grafts, mortality and morbidity: an analysis of 1,526,360 coronary bypass operations. *Heart.* 2013;99:849-53.
6. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. *Lancet.* 2001;358:870-5.
7. Grau JB, Ferrari G, Mak AW, Shaw RE, Brizzio ME, Mindich BP, Strobeck J, Zapolanski A. Propensity matched analysis of bilateral internal mammary artery versus single left internal mammary artery grafting at 17-year follow-up: validation of a contemporary surgical experience. *Eur J Cardiothorac Surg.* 2012;41:770-5; discussion 776.
8. Popovic B, Voillot D, Maureira P, Vanhuyse F, Agrinier N, Aliot E, Folliguet T, Villemot JP. BIMA bypass grafting: long-term clinical benefits in a series of 1000 patients. *Heart.* 2013;99:854-9.
9. Kelly R, Buth KJ, Légaré JF. Bilateral internal thoracic artery grafting is superior to other forms of multiple arterial grafting in providing survival benefit after coronary bypass surgery. *J Thorac Cardiovasc Surg.* 2012;144:1408-15.
10. Galbut DL, Kurlansky PA, Traad EA, Dorman MJ, Zucker M, Ebra G. Bilateral internal thoracic artery grafting improves long-term survival in patients with reduced ejection fraction: a propensity-matched study with 30-year follow-up. *J Thorac Cardiovasc Surg.* 2012;143:844-853.e4.

11. Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. *Circulation*. 2012;126:2935-42.
12. Puskas JD, Sadiq A, Vassiliades TA, Kilgo PD, Lattouf OM. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. *Ann Thorac Surg*. 2012;94:710-5; discussion 715-6.
13. Moshkovitz Y, Mohr R, Medalion B, Hyam E, Herz I, Deitch I, Uretzky G, Pevni D. Drug-eluting stents compared with bilateral internal thoracic artery grafts for diabetic patients. *Ann Thorac Surg*. 2012;94:1455-62.
14. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Bilateral internal mammary artery grafting reverses the negative influence of gender on outcomes of coronary artery bypass grafting surgery. *Eur J Cardiothorac Surg*. 2013;44:54-63.
15. Mohammadi S, Dagenais F, Doyle D, Mathieu P, Baillot R, Charbonneau E, Perron J, Voisine P. Age cut-off for the loss of benefit from bilateral internal thoracic artery grafting. *Eur J Cardiothorac Surg*. 2008;33:977-82.
16. Kieser TM, Lewin AM, Graham MM, Martin BJ, Galbraith PD, Rabi DM, Norris CM, Faris PD, Knudtson ML, Ghali WA; APPROACH Investigators. Outcomes associated with bilateral internal thoracic artery grafting: the importance of age. *Ann Thorac Surg*. 2011;92:1269-75; discussion 1275-6.
17. Elmistekawy EM, Gawad N, Bourke M, Mesana T, Boodhwani M, Rubens FD. Is bilateral internal thoracic artery use safe in the elderly? *J Card Surg*. 2012;27:1-5.
18. Puskas JD. Why did you not use both internal thoracic arteries? *Circulation*. 2012;126:2915-7.
19. Mastrobuoni S, Gawad N, Price J, Chan V, Ruel M, Mesana TG, Rubens FD. Use of bilateral internal thoracic artery during coronary artery bypass graft surgery in Canada: The bilateral internal thoracic artery survey. *J Thorac Cardiovasc Surg*. 2012;144:874-9.
20. Nauta ST, Van Mieghem NM, Magro M, Deckers JW, Simsek C, Van Geuns RJ, Van Der Giessen WJ, De Jaegere P, Regar E, Van Domburg RT, Serruys PW. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts. *Catheter Cardiovasc Interv*. 2012;79:912-8.